Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+\u2122 and Remplir\u2122.<\/p>\n
Orthocell has achieved a second consecutive quarter of record revenue, reporting revenue of $2.03m in the September \u201824 Quarter. Revenue is up 7.82% on the $1.88 million achieved in the June \u201824 Quarter, showing clear traction with new and existing surgeons, translating to growing sales of the Company\u2019s market-leading products Striate+\u2122 and Remplir\u2122<\/p>\n
Orthocell CEO and MD, Paul Anderson, said:<\/p>\n
\u201cWe are delighted with the continued growth in demand and record quarterly revenue for our market-leading products Striate+ and Remplir. These sales results demonstrate increasing market traction, which is driven by the consistent and predictable outcomes surgeons can achieve using our products. We are excited by the potential for exponential growth and believe we are on track to become a key player in a US$4 billion global market.\u201d<\/p>\n